VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc.
(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse
pipeline of novel, multifunctional biotherapeutics to improve the standard of
care for difficult-to-treat diseases, today announced that management will
report its second quarter 2024 financial results after market close on August
1, 2024. Following the announcement, management will host a conference call and
webcast to discuss financial results and provide a corporate update on August
1, 2024 at 4:30 pm Eastern Time (ET).
The event will be webcast live with dial-in details and webcast replays
available on Zymeworks' website at http://ir.zymeworks.com/events-and-
presentations
(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.zymeworks.
com%2Fevents-and-presentations&esheet=52946767&newsitemid=20221018005422&lan=en-
US&anchor=http%3A%2F%2Fir.zymeworks.com%2Fevents-and-
presentations&index=1&md5=1b88c3029ab4700ca28813caf136c0e5).
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the
discovery, development, and commercialization of novel, multifunctional
biotherapeutics. Zymeworks' mission is to make a meaningful difference in the
lives of people impacted by difficult-to-treat cancers and other diseases. The
Company's complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to precisely
engineer and develop highly differentiated antibody-based therapeutic
candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted
bispecific antibody using the Company's proprietary Azymetric(TM) technology.
Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and
Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to
develop and commercialize zanidatamab in different territories. Zanidatamab is
currently being evaluated in multiple global clinical trials as a potential
best-in-class treatment for patients with HER2-expressing cancers. A Biologics
License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking
accelerated approval for zanidatamab as a treatment for previously-treated,
unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer
(BTC) has been accepted and granted Priority Review. A BLA has also been
accepted for review by the Center for Drug Evaluation (CDE) of the National
Medical Products Administration (NMPA) in China. If approved, zanidatamab would
be the first HER2-targeted treatment specifically approved for BTC in the U.S.
and China. Zymeworks is rapidly advancing a deep pipeline of product candidates
based on its experience and capabilities in both antibody-drug conjugates and
multispecific antibody therapeutics across multiple novel targets in indications
that represent areas of significant unmet medical need. In addition to
Zymeworks' wholly owned pipeline, its therapeutic platforms have been further
leveraged through strategic partnerships with global biopharmaceutical
companies. For information about Zymeworks, visit www.zymeworks.com
(https://www.zymeworks.com/) and follow @ZymeworksInc
(https://twitter.com/ZymeworksInc) on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388?
ir@zymeworks.com (mailto:ir@zymeworks.com)??
investors@zymeworks.com (mailto:investors@zymeworks.com)
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388?
ir@zymeworks.com (mailto:ir@zymeworks.com)??
media@zymeworks.com (mailto:media@zymeworks.com)
Â